Transient downmodulation of CD20 by rituximab.

被引：0
|
作者：
Jilani, I [1 ]
O'Brien, S [1 ]
Manshouri, T [1 ]
Thomas, DA [1 ]
Thomazy, VA [1 ]
Imam, M [1 ]
Naeem, S [1 ]
Verstovsek, S [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
Keating, M [1 ]
Albitar, M [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3174
引用
收藏
页码：804A / 804A
页数：1
相关论文
共 50 条
  • [21] 抗CD20单克隆抗体—Rituximab
    赵江宁
    朱雅丽
    白血病淋巴瘤., 2004, (02) : 123 - 125
  • [22] Upregulation of CD20 on human acute lymphoblastic leukemia cells by IL-4 and CpG motif containing oligonucleotides increases susceptibility to rituximab.
    Nijmeijer, Bart
    Van Schie, Marianke L. J.
    Willemze, Roelof
    Falkenburg, J. H. Frederik
    BLOOD, 2006, 108 (11) : 533A - 533A
  • [23] Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris
    El Tal, Abdul Kader
    Posner, Marshall R.
    Spigelman, Zachary
    Ahmed, A. Razzaque
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (03) : 449 - 459
  • [24] Loss of CD20 expression on CLL cells following treatment with rituximab
    Poirot, Brigitte
    Chedani, Hicham
    Abbed, Karim
    Tertian, Gerard
    Raphael, Martine
    Besson, Caroline
    HEMATOLOGIE, 2010, 16 (01): : 92 - 95
  • [25] Loss of CD20 expression in relapsed lymphomas after rituximab therapy
    Haidar, JH
    Shamseddine, A
    Salem, Z
    Mrad, YA
    Nasr, MR
    Zaatari, G
    Bazarbachi, A
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2003, 70 (05) : 330 - 332
  • [26] CD20
    Warzynski, MJ
    Graham, DM
    Axtell, RA
    Zakem, MH
    Rotman, RK
    APPLIED IMMUNOHISTOCHEMISTRY, 1996, 4 (03): : 218 - 218
  • [27] CD20
    Macardle, PJ
    Nicholson, IC
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2002, 16 (02): : 136 - 138
  • [28] Treatment of chronic lymphocytic leukemia (CLL)with the anti-CD20 antibody rituximab.
    Emmerich, B
    Huhn, D
    Peschel, C
    Wilhelm, M
    von Schilling, C
    Bentz, M
    Hallek, M
    Knauf, B
    Kuse, R
    Ho, AD
    BLOOD, 1999, 94 (10) : 309B - 309B
  • [29] MONITORING OF IMMUNOGLOBULIN LEVELS IN RA PATIENTS ON ANTI CD20, RITUXIMAB
    Rice, Ceara
    Ghandi-Das, Dhivya
    Negi, Anurag
    RHEUMATOLOGY, 2020, 59 : 94 - 94
  • [30] Anti CD20 (Rituximab) therapy in refractory pediatric rheumatic diseases
    Reis, J.
    Aguiar, F.
    Brito, I
    ACTA REUMATOLOGICA PORTUGUESA, 2016, 41 (01): : 45 - 55
12345